Technologies Transforming the Biomanufacturing Landscape

Technologies Transforming the Biomanufacturing Landscape

Translating Technology Innovation to Market Competitiveness

RELEASE DATE
25-Jun-2019
REGION
Global
Research Code: D8BA-01-00-00-00
SKU: HC03189-GL-TR_23302
AvailableYesPDF Download
$4,950.00
In stock
SKU
HC03189-GL-TR_23302
$4,950.00
DownloadLink
ENQUIRE NOW

Description

Overall Impact of Biomanufacturing Technology Innovations
Impact on Unmet Needs
Pharmaceutical companies perceive analytical services as important. There is a need for a robust platform that enables the provision of such services. Pharma firms are outsourcing crucial processes and are utilizing services such as analytics, research, process development, bio-analytical testing, and regulatory support.

Impact on Capturing Investment Opportunities
As the biologics market is witnessing increased outsourcing of mammalian cell culture activities, a significant expansion of capacity is expected in this area. Biopharma companies will outsource cell line development to specialist vendors, including professional biological contract manufacturing organizations (BioCMOs), or license it from them.

Impact on Technology Implementation
Contract development and manufacturing organizations (CDMOs) need to focus on the attractive opportunity in disposables/ single use bioreactors, improvements in upstream & downstream technologies, advances in lyophilisation & increased application of PAT, continuous bio-manufacturing, new cell culture techniques, and modular facilities/pod manufacturing.

Impact on Strategic Collaborations
CDMOs need to broaden their services to grab emerging opportunities in outsourcing of biologic and biosimilar manufacturing driven by mid and small biotech names. Large BioCDMOs will continue to invest in drug development and clinical manufacturing capabilities through M&A activities.

Impact on Disruptive Business Models
Expanding services of CMOs into the early-stage development of drugs, emergence of virtual biotech, out-licensing, and risk sharing between pharma and CMOs is disrupting the traditional business models. By offering value-added services to pharma companies, CMOs need to redefine themselves as CDMOs and integrate themselves into the value chain of companies.

Table of Contents

1.1 Research Focus: Biomanufacturing Technology Synergy

1.2 Research Scope: Foreseeing Challenges and Solutions

1.3 Analysis Framework: Frost & Sullivan’s Core Value

1.4 Research Methodology

2.1 Biomanufacturing Facts and Challenges

2.2 Biomanufacturing Complexity

2.3 Biomanufacturing Growth Opportunities

3.1 Biopharmaceutical Manufacturing: Smart Industrial Operations

3.2 Biopharmaceutical Manufacturing: Process Intensification

3.3 Biopharmaceutical Manufacturing: Upstream

3.4 Biopharmaceutical Manufacturing: Downstream

3.5 Biopharmaceutical Manufacturing: Different Levels of Flexibility

3.6 Process Technology Disruptiveness Opportunities

3.7 Bioprocessing Units and Facility Types: Fed Batch

3.8 Large-scale Stainless Steel Fed Batch

3.9 Bioprocessing Units and Facility Types: Single Use Bioreactors

3.10 Single Use Bioreactors

3.11 Bioprocessing Units and Facility Types: Small-scale Bioreactors

3.12 Small Scale Bioreactors

4.1 Biomonitoring Technology Coming Next Decade

4.2 Evolving Process Control and Monitoring: Value Chain Excellence

4.3 Analysis of Key Biomonitoring Trends

4.4 Biomonitoring, Process Solutions Services and Bioprocessing

4.5 Evolving Process Control and Monitoring

4.6 Innovations in Biomonitoring Systems

4.7 Roadmap for Biomonitoring Systems

5.1 Biomonitoring Market Potential

5.2 Overall Environmental Impact Factors

5.3 Best-fit Industry Partnerships: SWOT Analysis

5.4 Novel Business Models in Biomanufacturing

5.5 Partners Business and Technology Capabilities

5.6 Market Adoption: Illustrative Case Using Single Use Technology

6.1 Actionable Impact on Customers

6.2 Insights on Bioprocessing

6.3 Repercussions in Business and Processes

6.4 Technology Transfer Assessment

7.1 Typical Value Chain Interactive Model

7.2 Biomanufacturing Technology Roadmap

7.3 Industry Intersection Model

7.4 Crossmapping Continuous Monitoring Innovations

7.5 Key Remarks to Success in the Industry 4.0 Era

8.1 Biomonitoring Assessment and Prioritization Criteria

8.2 Transformation in Industry Eco-system

8.3 Companies Leading the Biomanufacturing Space

8.4 Biomanufacturing Competitive Environment

8.5 Major Stakeholders: Lonza

8.6 Lonza Value Proposition

8.7 Major Stakeholders: Boehringer Ingelheim (BioXcellence)

8.8 Boehringer Ingelheim Value Proposition

8.9 Major Stakeholders: Catalent

8.10 Catalent Value Proposition

8.11 Major Stakeholders: Patheon (Thermo Fisher Scientific)

8.12 Patheon Value Proposition

8.13 Major Stakeholders: Samsung BioLogics

8.14 Samsung BioLogics Value Proposition

8.15 Major Stakeholders: Wuxi Biologics

8.16 Wuxi Biologics Value Proposition

8.17 Major Stakeholders: AGC Biologics

8.18 AGC Biologics Value Proposition

8.19 The Final Chart: Innovation Index Radar

8.20 Strategic Imperatives for Future Growth

9.1 Key Industry Influencers

9.2 Key Industry Experts

9.3 Key Industry Authorities

9.4 Key Industry Advisors

9.5 Key Industry Mentors

Legal Disclaimer

Related Research
Overall Impact of Biomanufacturing Technology Innovations Impact on Unmet Needs Pharmaceutical companies perceive analytical services as important. There is a need for a robust platform that enables the provision of such services. Pharma firms are outsourcing crucial processes and are utilizing services such as analytics, research, process development, bio-analytical testing, and regulatory support. Impact on Capturing Investment Opportunities As the biologics market is witnessing increased outsourcing of mammalian cell culture activities, a significant expansion of capacity is expected in this area. Biopharma companies will outsource cell line development to specialist vendors, including professional biological contract manufacturing organizations (BioCMOs), or license it from them. Impact on Technology Implementation Contract development and manufacturing organizations (CDMOs) need to focus on the attractive opportunity in disposables/ single use bioreactors, improvements in upstream & downstream technologies, advances in lyophilisation & increased application of PAT, continuous bio-manufacturing, new cell culture techniques, and modular facilities/pod manufacturing. Impact on Strategic Collaborations CDMOs need to broaden their services to grab emerging opportunities in outsourcing of biologic and biosimilar manufacturing driven by mid and small biotech names. Large BioCDMOs will continue to invest in drug development and clinical manufacturing capabilities through M&A activities. Impact on Disruptive Business Models Expanding services of CMOs into the early-stage development of drugs, emergence of virtual biotech, out-licensing, and risk sharing between pharma and CMOs is disrupting the traditional business models. By offering value-added services to pharma companies, CMOs need to redefine themselves as CDMOs and integrate themselves into the value chain of companies.
More Information
No Index No
Podcast No
Author Cecilia Van Cauwenberghe
Industries Healthcare
WIP Number D8BA-01-00-00-00
Is Prebook No